Fed. Circ. Appears To Side With Eli Lilly Over Cancer Patent
A Federal Circuit panel appeared to disagree Tuesday with Neptune Generics LLC's argument that a patent protecting the vitamin regimen for one of drugmaker Eli Lilly & Co.'s best-selling cancer treatments...To view the full article, register now.
Already a subscriber? Click here to view full article